Passage Bio Reports Promising Interim Data in FTD-GRN Treatment Trial
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) recently shared its first-quarter financials and highlighted recent advancements in its clinical trials. Among the key updates, interim data from its upliFT-D …
Passage Bio Reports Promising Interim Data in FTD-GRN Treatment Trial Read More